Researchers analyzed 10 randomized controlled trials and 30 observational studies with 5,668 patients.
Here’s what they found.
1. There was moderate-quality evidence for improvement in most metabolic parameters for subjects assigned to intragastric balloon therapy compared to conventional non-surgical therapy.
2. The odds ratio for diabetes resolution after intragastric balloons therapy was 1.4.
3. The balloons had a 1.3 percent rate of serious adverse events.
Researchers concluded, “IGBs are more effective than diet in improving obesity-related metabolic risk factors with a low rate of adverse effects, however the strength of the evidence is limited given the small number of participants and lack of long-term follow-up.”
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Anthony Grande of North Suburban Gastroenterology Associates
Allergan makes board changes: 3 things to know
Chemotherapy overused for young, middle-aged adults with colon cancer, no improvement in survival rate: 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.